Scpharmaceuticals (NASDAQ: SCPH) is one of 497 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Scpharmaceuticals to related businesses based on the strength of its profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.
This is a breakdown of recent ratings and price targets for Scpharmaceuticals and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Valuation & Earnings
This table compares Scpharmaceuticals and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Scpharmaceuticals Competitors||$2.00 billion||$130.71 million||-3.12|
Scpharmaceuticals’ rivals have higher revenue and earnings than Scpharmaceuticals. Scpharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
44.9% of Scpharmaceuticals shares are owned by institutional investors. Comparatively, 47.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 4.8% of Scpharmaceuticals shares are owned by company insiders. Comparatively, 15.7% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This table compares Scpharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Scpharmaceuticals beats its rivals on 7 of the 12 factors compared.
Scpharmaceuticals Company Profile
scPharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix, a drug-device combination product that is under development for treatment of worsening or decompensated heart failure outside of the inpatient setting. Its product pipeline also includes scFurosemide, a loop diuretic for the management of edema in patients with decompensated heart failure; scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company was founded in 2013 and is headquartered in Burlington, Massachusetts.
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.